2.57
+0.06
(2.39%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.40 - 2.57 |
| 52 week | 2.04 - 4.93 |
| Open | 2.50 |
| Vol / Avg. | 216,549.00/235,727.00 |
| Mkt cap | 172.63M |
| P/E | - |
| Div/yield | - |
| EPS | -0.50 |
| Shares | 67.17M |
| Beta | 1.90 |
| Inst. own | 22% |
Events
Aug 5, 2013
Q2 2013 Cytori Therapeutics Earnings Release
Jul 18, 2013
Cytori Therapeutics Annual Shareholder Meeting
- 12:00PM EDT -
May 9, 2013
Q1 2013 Cytori Therapeutics Earnings Conference Call
May 9, 2013
Q1 2013 Cytori Therapeutics Earnings Release
Apr 17, 2013
Cytori Therapeutics at Alliance for Regenerative Medicine RegenMed Investor Day
Apr 5, 2013
Cytori Therapeutics at BioCentury Publications Future Leaders in the Biotech Industry Conference -
Mar 18, 2013
Cytori Therapeutics at Roth Conference
Mar 7, 2013
Q4 2012 Cytori Therapeutics Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -204.02% | -222.60% |
| Operating margin | -179.27% | -195.97% |
| EBITD margin | - | -187.31% |
| Return on average assets | -80.28% | -68.11% |
| Return on average equity | -697.09% | -393.62% |
| Employees | 127 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Cytori Therapeutics, Inc. develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company's clinical pipeline is for cardiovascular disease. The Company�s products include Celbrush, Puregraft, and Cytori LipoBank. The Celbrush is available in the 10 milliliter and 3 milliliter sizes and is used in conjunction with a Soft-Ject Syringe in the corresponding size. The Puregraft System is developed for autologous fat grafting and aesthetic body contouring. The Puregraft System is available in two sizes: 250 milliliter, which processes 50-250 milliliter of tissue, and 850 milliliter, which processes 200-850 milliliter of tissue. The Cytori LipoBank is a GTP-compliant cryopreservation system that offers a long-term storage option for viable adipose tissue after a single liposuction.
Officers and directors
| Lloyd H. Dean | Independent Chairman of the Board | |
| Marc H. Hedrick M.D. | President, Director | |
| Christopher J. Calhoun | Chief Executive Officer, Director | |
| Mark E. Saad | Chief Financial Officer | |
| Seijiro N. Shirahama | President , Asia Pacific | |
| Clyde W. Shores | Executive Vice President - Marketing & Sales | |
| Steven Kesten M.D. | Executive Vice President, Chief Medical Officer | |
| Richard J Hawkins | Independent Director | |
| Paul W. Hawran CPA | Independent Director | |
| E. Carmack Holmes M.D. | Independent Director |